Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
Identifieur interne : 000202 ( PubMed/Corpus ); précédent : 000201; suivant : 000203Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
Auteurs : James M. Sanders ; Marguerite L. Monogue ; Tomasz Z. Jodlowski ; James B. CutrellSource :
- JAMA [ 1538-3598 ] ; 2020.
Abstract
The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment. Given the rapid pace of scientific discovery and clinical data generated by the large number of people rapidly infected by SARS-CoV-2, clinicians need accurate evidence regarding effective medical treatments for this infection.
DOI: 10.1001/jama.2020.6019
PubMed: 32282022
Links to Exploration step
pubmed:32282022Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.</title><author><name sortKey="Sanders, James M" sort="Sanders, James M" uniqKey="Sanders J" first="James M" last="Sanders">James M. Sanders</name><affiliation><nlm:affiliation>Department of Pharmacy, University of Texas Southwestern Medical Center, Dallas.</nlm:affiliation></affiliation></author><author><name sortKey="Monogue, Marguerite L" sort="Monogue, Marguerite L" uniqKey="Monogue M" first="Marguerite L" last="Monogue">Marguerite L. Monogue</name><affiliation><nlm:affiliation>Department of Pharmacy, University of Texas Southwestern Medical Center, Dallas.</nlm:affiliation></affiliation></author><author><name sortKey="Jodlowski, Tomasz Z" sort="Jodlowski, Tomasz Z" uniqKey="Jodlowski T" first="Tomasz Z" last="Jodlowski">Tomasz Z. Jodlowski</name><affiliation><nlm:affiliation>Pharmacy Service, VA North Texas Health Care System, Dallas.</nlm:affiliation></affiliation></author><author><name sortKey="Cutrell, James B" sort="Cutrell, James B" uniqKey="Cutrell J" first="James B" last="Cutrell">James B. Cutrell</name><affiliation><nlm:affiliation>Division of Infectious Diseases and Geographic Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32282022</idno><idno type="pmid">32282022</idno><idno type="doi">10.1001/jama.2020.6019</idno><idno type="wicri:Area/PubMed/Corpus">000202</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000202</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.</title><author><name sortKey="Sanders, James M" sort="Sanders, James M" uniqKey="Sanders J" first="James M" last="Sanders">James M. Sanders</name><affiliation><nlm:affiliation>Department of Pharmacy, University of Texas Southwestern Medical Center, Dallas.</nlm:affiliation></affiliation></author><author><name sortKey="Monogue, Marguerite L" sort="Monogue, Marguerite L" uniqKey="Monogue M" first="Marguerite L" last="Monogue">Marguerite L. Monogue</name><affiliation><nlm:affiliation>Department of Pharmacy, University of Texas Southwestern Medical Center, Dallas.</nlm:affiliation></affiliation></author><author><name sortKey="Jodlowski, Tomasz Z" sort="Jodlowski, Tomasz Z" uniqKey="Jodlowski T" first="Tomasz Z" last="Jodlowski">Tomasz Z. Jodlowski</name><affiliation><nlm:affiliation>Pharmacy Service, VA North Texas Health Care System, Dallas.</nlm:affiliation></affiliation></author><author><name sortKey="Cutrell, James B" sort="Cutrell, James B" uniqKey="Cutrell J" first="James B" last="Cutrell">James B. Cutrell</name><affiliation><nlm:affiliation>Division of Infectious Diseases and Geographic Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas.</nlm:affiliation></affiliation></author></analytic><series><title level="j">JAMA</title><idno type="eISSN">1538-3598</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment. Given the rapid pace of scientific discovery and clinical data generated by the large number of people rapidly infected by SARS-CoV-2, clinicians need accurate evidence regarding effective medical treatments for this infection.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32282022</PMID><DateRevised><Year>2020</Year><Month>04</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Apr</Month><Day>13</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2020.6019</ELocationID><Abstract><AbstractText Label="Importance" NlmCategory="UNASSIGNED">The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment. Given the rapid pace of scientific discovery and clinical data generated by the large number of people rapidly infected by SARS-CoV-2, clinicians need accurate evidence regarding effective medical treatments for this infection.</AbstractText><AbstractText Label="Observations" NlmCategory="UNASSIGNED">No proven effective therapies for this virus currently exist. The rapidly expanding knowledge regarding SARS-CoV-2 virology provides a significant number of potential drug targets. The most promising therapy is remdesivir. Remdesivir has potent in vitro activity against SARS-CoV-2, but it is not US Food and Drug Administration approved and currently is being tested in ongoing randomized trials. Oseltamivir has not been shown to have efficacy, and corticosteroids are currently not recommended. Current clinical evidence does not support stopping angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients with COVID-19.</AbstractText><AbstractText Label="Conclusions and Relevance" NlmCategory="UNASSIGNED">The COVID-19 pandemic represents the greatest global public health crisis of this generation and, potentially, since the pandemic influenza outbreak of 1918. The speed and volume of clinical trials launched to investigate potential therapies for COVID-19 highlight both the need and capability to produce high-quality evidence even in the middle of a pandemic. No therapies have been shown effective to date.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sanders</LastName><ForeName>James M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, University of Texas Southwestern Medical Center, Dallas.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases and Geographic Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monogue</LastName><ForeName>Marguerite L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, University of Texas Southwestern Medical Center, Dallas.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases and Geographic Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jodlowski</LastName><ForeName>Tomasz Z</ForeName><Initials>TZ</Initials><AffiliationInfo><Affiliation>Pharmacy Service, VA North Texas Health Care System, Dallas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cutrell</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Geographic Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32282022</ArticleId><ArticleId IdType="pii">2764727</ArticleId><ArticleId IdType="doi">10.1001/jama.2020.6019</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000202 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000202 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:32282022
|texte= Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:32282022" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |